[
    [
        {
            "time": "",
            "original_text": "智飞生物董事长蒋仁生获全国非公经济人士优秀建设者称号",
            "features": {
                "keywords": [
                    "智飞生物",
                    "董事长",
                    "蒋仁生",
                    "非公经济",
                    "优秀建设者"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "智飞生物董事长蒋仁生获全国非公经济人士优秀建设者称号",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 8,
                "Market_Scope": 2,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "渝股点金｜估值再次回归合理区间 涪陵榨菜值得关注",
            "features": {
                "keywords": [
                    "渝股",
                    "涪陵榨菜",
                    "估值",
                    "合理区间"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "食品"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "渝股点金｜估值再次回归合理区间 涪陵榨菜值得关注",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "康华生物：主打产品获批涉及行贿 销售费用逐年增高 其他违规处罚",
            "features": {
                "keywords": [
                    "康华生物",
                    "主打产品",
                    "行贿",
                    "销售费用",
                    "违规处罚"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "康华生物：主打产品获批涉及行贿 销售费用逐年增高 其他违规处罚",
                "Correlation": 9,
                "Sentiment": 2,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "【国元医药】代理产品高速增长，后续在研可期 ——智飞生物2019H1中报点评",
            "features": {
                "keywords": [
                    "国元医药",
                    "智飞生物",
                    "代理产品",
                    "高速增长",
                    "在研可期",
                    "2019H1中报"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【国元医药】代理产品高速增长，后续在研可期 ——智飞生物2019H1中报点评",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "智飞生物:业绩符合预期,HPV疫苗持续放量带动公司高增长",
            "features": {
                "keywords": [
                    "智飞生物",
                    "业绩",
                    "HPV疫苗",
                    "持续放量",
                    "高增长"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "智飞生物:业绩符合预期,HPV疫苗持续放量带动公司高增长",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "智飞生物2019H1中报点评:代理产品高速增长,后续在研可期",
            "features": {
                "keywords": [
                    "智飞生物",
                    "2019H1中报",
                    "代理产品",
                    "高速增长",
                    "在研可期"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "智飞生物2019H1中报点评:代理产品高速增长,后续在研可期",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        }
    ]
]